Advances in the Diagnosis and Treatment of Kidney Disease

Guest Editors:

Dr. Shen-ju Gou
West China Hospital of Sichuan University, Chengdu, China

Dr. Liang Ma
Division of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 332001, China

Deadline for manuscript submissions:
closed (10 August 2023)

Message from the Guest Editors

The incidence of kidney disease is very high. Uremia, the renal endpoint of all kinds of kidney disease, impose a heavy burden on society. In recent years, many breakthroughs have been made in the pathogenesis of primary kidney disease, secondary kidney disease, and inherited kidney disease. Many new discoveries have been made in the search for molecular biomarkers of kidney disease. Clinical trials of new drugs for kidney disease have contributed greatly to the progress in treatment.

The aim of this Special Issue is to provide a publishing platform for the discoveries and progress in all kinds of kidney diseases. Basic research focused on the pathogenesis, clinical trials of new drugs, and reviews of the diagnosis and treatment of kidney diseases are welcome for submission. We hope that this Special Issue will shed light on the pathogenesis of kidney disease and promote progress in the diagnosis and treatment of kidney diseases. We invite original research, reviews, etc., that focus on the latest research progress in the diagnosis and treatment of kidney diseases.

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us